NEWS & COMMENTS

PROHOST    FILTER

PROHOST MAIL

     Dear Prohost,

     Was wondering your thoughts on MITI after the announcement with MEDI? As always thank you for your insight. Talk to you soon.

Best wishes,

S. C

What this letter is about?

     MedImmune Inc. filed an investigational new drug application with the FDA for a prospective treatment of B cell derived non-Hodgkins lymphoma. The drug is known as MT103 or MEDI-538.  The filing has triggered a milestone payment of an undisclosed sum to development partner Micromet (MTIT). According to MedImmune, the drug will be tested for safety and tolerability during a Phase I trial. The study will build upon clinical progress made in European studies by Micromet, Micromet is testing continuous infusion of the drug in patients for periods of four to eight weeks in a Phase I trial.

Prohost response

Dear friend

     MT103 or MEDI-538 could be a breakthrough drug and MITI is definitely behind it.  MEDIMMUNE is surely impressed with this drug, especially after a successful testing it in Europe. As a result, we also felt good about it, but not without verification. As a matter of fact, we did verify and liked the concept and the prospects. Yet, we asked ourselves, who else cares?

     We will recognize the degree of investors' enthusiasm after the FDA's response to MedImmune's filing, which we are confident it will be positive. At that time we will decide whether we buy the stock so early, or wait until the general investor becomes aware of the drug and of the firm’s fundamentals. The stock  sells at only $2.5. Yet, the reaction after the acceptance of the filing will show a lot more about investors' awareness and enthusiasm. Otherwise, it would depend on Micromet's other activities, which we are in the process of scrutinizing.

     Wait and see could be the best attitude at this moment until our verification will be complete.

Dendreon’s (DNDN) shares rose last Thursday after the firm announced it submitted the clinical and nonclinical portions of its biologics license application (BLA) to the FDA for its Provenge cancer drug for approval.. The last step, the chemistry-manufacturing-controls (CMC) section, is expected to be also submitted later this year.

According to the Company, Provenge confers an advantage in overall survival, without significant toxicity, to men with asymptomatic, metastatic, androgen-independent prostate cancer. Dr. Mitchell Gold, president and CEO, of Dendreon said, "Based upon the results of our clinical trials, we believe that Provenge has a highly favorable benefit-to-risk profile, and we are focused on working closely with the FDA so that Provenge can be made available to help prostate cancer patients."

We too are optimistic.  

Activities in Sequenom? Read the upcoming E-letter that will be posted tomorrow.

Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: http://www.sec.gov/consumer/cyberfr.htm